Controlled of women with 17-beta-estradiol vasomotor (3) Yes** ≥2 Low-Dose Estradiol bothersome 0.5-mg/day, symptoms Estradiol vs (4) Yes** and the vasomotor dose venlafaxine Placebo, (5) Yes** SNRI Venlafaxine symptoms per day XR 75-mg/day for difference EB risk of bias: for Vasomotor (mean 8.1, SD 8 weeks Low Symptoms 5.3/day) Baseline: 8.5 (7.4, 9.7) vs 7.7 (6.9, 8.5), N = 339 0.9 (−0.5, 2.2) Age = 40-62 years Duration = 8 Week 4: (−4.0, −3.1 Follow-up = at 8 or vs (−2.5, −2.3) −1.9 12 weeks (−2.2, −1.3), −1.2 −0.2) Week 8: (−5.4, −4.5 vs (−2.8, −3.6) −2.2 (−3.4, −1.6), −2.3 −1.3) p<0.001* Venlafaxine vs Placebo, difference Baseline: 8.2 (7.1, 9.3) vs 7.7 (6.9, 8.5), 0.5 (−0.8, 1.8) Week 4: (−4.0, −3.3 vs (−2.5, −2.5) −1.9 (−2.3, −1.3), −1.4 −0.4)
Controlled of Low-Dose Estradiol and the SNRI Venlafaxine for Vasomotor Symptoms N = 339 Age = 40-62 years Duration = 8 Follow-up = at 8 or 12 weeks women with ≥2 bothersome vasomotor symptoms per day (mean 8.1, SD 5.3/day) 17-beta-estradiol 0.5-mg/day, venlafaxine XR 75-mg/day for 8 weeks vasomotor symptoms Estradiol vs Placebo, difference Baseline: 8.5 (7.4, 9.7) vs 7.7 (6.9, 8.5), 0.9 (−0.5, 2.2) Week 4: −3.1 (−4.0, −2.3) vs −1.9 (−2.5, −1.3), −1.2 (−2.2, −0.2) Week 8: −4.5 (−5.4, −3.6) vs −2.2 (−2.8, −1.6), −2.3 (−3.4, −1.3) p<0.001* Venlafaxine vs Placebo, difference Baseline: 8.2 (7.1, 9.3) vs 7.7 (6.9, 8.5), 0.5 (−0.8, 1.8) Week 4: −3.3 (−4.0, −2.5) vs −1.9 (−2.5, −1.3), −1.4 (−2.3, −0.4) (3) Yes** (4) Yes** (5) Yes** EB risk of bias: Low dose